恩替卡韦治疗慢性乙型肝炎临床疗效及安全性分析-论文.pdf

《恩替卡韦治疗慢性乙型肝炎临床疗效及安全性分析-论文.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。

1、中国煤炭工业医学杂志2014年7月第17卷第7期ChineseJournalofCoalIndustryMedicine，Ju1．2014，Vo1．17，No．7·1069·恩替卡韦治疗慢性乙型肝炎临床疗效及安全性分析谢琳琳李文玉摘要目的探讨恩替卡韦(ETV)治疗慢性乙型肝炎临床疗效及安全性。方法将8O例慢性乙肝患者按照抽签方法随机均分为对照组与观察组，各为40例。观察组给予0．5mg／d的ETV治疗，对照组给予100mg／d的拉米夫定(LAM)治疗。比较二组治疗前后肝功能指标变化、超声影像学指标变化、治疗后HBV—DNA滴度与转阴率、不良反应。结果①二组治疗前

2、后肝功能指标(ALT、ALB及TBil)相比，差异均具有统计学意义(P0．05)；③二组治疗前后HBV—DNA滴度相比，差异均具有统计学意义(P

3、应发生。结论与LAM相比，ETV治疗慢性乙肝疗效更为显著，安全性高，应在临床上进行推广及应用。关键词恩替卡韦；拉米夫定；慢性乙肝；用药安全性中图分类号R512．62文献标识码B文章编号1007—9564(2014)07—1069—03D0I编码10．11723／mtgyyx1007—9564201407012EFFICACYANDSAFETYOFENTECAVIRINTREAI’MENI’OFCHRONICHEPATITISBeLinlin。LiWenyu．BinzhouPeople'sHospital。Bingzhou256600-China‘Abstract

4、0bjectiveToinvestigatetheefficacyandsafetyofentecavir(ETV)intreatmentofchronichep—atitisB．MethodsAtotalof80patientswithchronichepatitisBweredividedintocontro1groupandob—servationgroupwithasimpledrawingrandom。eachwith40cases．Observationgroupreceived0．5mg／dofETV。thecontrolgroupwasgiven

5、100mg／doflamivudine(LAM)．Changesinliverfunction，ultra—soundimagingindexwerecomparedbeforeandaftertreatment，HBV—DNAtiters-thenegativerateandadversereactionsratewerecomparedaftertreatment．ResultsThedifferenceofliverfunction(ALT。ALBandTBil)inthetwogroupswasstatisticallysignificantbefore

6、andaftertreatment(P<0．05，P<0．01)-andthedifferencebetweenthetwogroupsafterthetreatmentoftheseindicatorswasalsostatisti—callysignificance(P<0．05)．Aftertreatment，thedifferenceofultrasoundimagingindicatorswerestatis—ticallysignificantbetweenthetwogroups(P<0．05)。buttultrasoundimagingindic

7、atorswerenostatisticaldifference(P>0．05)．TherewasstatisticallydifferenceofHBV—DNAtitersbeforeandaftertreatment(P<0．05)-anditwasalsosameasbetweenthetwogroups(P<0．05)．TheHBV—DNAnegativerateaftertreatmentinobservationgroupwas90．O0。whichwassignificantlyhigherthanthatinthecontrolgroup(72．

8、50)(P<0．05)．